نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

Journal: :Haematologica 2014
María-Victoria Mateos Sara Bringhen Paul G Richardson Juan Jose Lahuerta Alessandra Larocca Albert Oriol Mario Boccadoro Ramón García-Sanz Francesco Di Raimondo Dixie-Lee Esseltine Helgi van de Velde Avinash Desai Anil Londhe Jesús F San Miguel Antonio Palumbo

Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week once-weekly cycles. In the GIMEMA MM-03-05 study, the bortezomib-melphalan-prednisone regimen was ei...

Journal: :Haematologica 2015
Michel Delforge Leonard Minuk Jean-Claude Eisenmann Bertrand Arnulf Letizia Canepa Alberto Fragasso Serge Leyvraz Christian Langer Yousef Ezaydi Dan T Vogl Pilar Giraldo-Castellano Sung-Soo Yoon Charles Zarnitsky Martine Escoffre-Barbe Bernard Lemieux Kevin Song Nizar Jacques Bahlis Shien Guo Mara Silva Monzini Annette Ervin-Haynes Vanessa Houck Thierry Facon

We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednis...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 1998
H R Alexander C K Brown D L Bartlett S K Libutti W D Figg S Raje E Turner

Isolated organ perfusion of the liver or extremity with tumor necrosis factor (TNF) and melphalan results in regression of bulky tumors in the majority of patients. The efficacy of TNF in this setting is not known, although data suggest that it may exert antitumor effects primarily on tumor-associated neovasculature. We studied the effects of TNF on capillary leak in liver and tumor tissue duri...

2011
Lejla Mutapcic Vajzovic Timothy G Murray Mohammad A Aziz-Sultan Amy C Schefler Stacey Quintero Wolfe Ditte Hess Cristina E Fernandes Sander R Dubovy

PURPOSE The purpose of this study is to report the complication profile and safety evaluation of supraselective intra-arterial melphalan chemotherapy in children undergoing treatment with advanced retinoblastoma. METHODS Twelve eyes of 10 children with advanced retinoblastoma (Reese-Ellsworth Group Vb or International Classification Group D) were treated with supraselective intra-ophthalmic a...

2006
P. J. Selby G. G. Steel

Human melanoma xenografts in immune-deprived mice have been used to assess the value of the agar diffusion chamber for chemosensitivity testing. Tumor cells were treated with melphalan, Adriamycin, or methyl frans-1-(2-chloroethyl)-3-(4methylcyclohexyl)-1 -nitrosourea either as solid tumors growing in mice or as suspensions in agar in i.p. diffusion chambers. Survival of clonogenic human tumor ...

Journal: :JAMA ophthalmology 2015
Jasmine H Francis Brian P Marr Scott E Brodie David H Abramson

IMPORTANCE Intravitreous injections of melphalan hydrochloride are increasingly used in the treatment of vitreous seeding of retinoblastoma. Although this technique can save eyes otherwise destined for enucleation, ocular salvage may be accompanied by local toxic effects. Posterior segment toxic effects in this context are well established. This report describes the toxic effects on the anterio...

Journal: :Biochemical pharmacology 2009
Luke R E Harrison Christopher J Ottley D Graham Pearson Céline Roche Stephen R Wedge M Eileen Dolan David R Newell Michael J Tilby

O(6)-Cyclohexylmethylguanine (NU2058) was developed as an inhibitor of CDK2 and was previously shown to potentiate cisplatin cytotoxicity in vitro. The aim of this study was to investigate the mechanism of cisplatin potentiation by NU2058. SQ20b, head and neck cancer cells were treated for 2h with NU2058 (100 microM) and then for a further 2h with cisplatin and NU2058. NU2058 increased cisplati...

Journal: :Molecular cancer therapeutics 2012
Heather J Landau Samuel C McNeely Jayasree S Nair Raymond L Comenzo Takashi Asai Hillel Friedman Suresh C Jhanwar Stephen D Nimer Gary K Schwartz

DNA cross-linking agents are frequently used in the treatment of multiple myeloma-generating lesions, which activate checkpoint kinase 1 (Chk1), a critical transducer of the DNA damage response. Chk1 activation promotes cell survival by regulating cell-cycle arrest and DNA repair following genotoxic stress. The ability of AZD7762, an ATP-competitive Chk1/2 inhibitor to increase the efficacy of ...

2017
Malin Wickström Peter Nygren Rolf Larsson Johan Harmenberg Jakob Lindberg Per Sjöberg Markus Jerling Fredrik Lehmann Paul Richardson Kenneth Anderson Dharminder Chauhan Joachim Gullbo

Aminopeptidases like aminopeptidase N (APN, also known as CD13) play an important role not only in normal cellular functioning but also in the development of cancer, including processes like tumor cell invasion, differentiation, proliferation, apoptosis, motility, and angiogenesis. An increased expression of APN has been described in several types of human malignancies, especially those charact...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید